Results 91 to 100 of about 44,899 (264)

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

Clinical Pharmacology &Therapeutics, EarlyView.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore, Melissa S. Bourque, Andreas Halman, José A. G. Agúndez, Cynthia A. Prows, Keiko Hikino, Matthias Schwab, Carolyn J. Oxencis, Dharmisha Chauhan, Meta H.M. Diekstra, Susie E. Long, Gillian C. Bell, Andrea Gaedigk, Michelle Whirl‐Carrillo, Teri E. Klein, Kelly E. Caudle, Rachel Conyers   +16 more
wiley   +1 more source

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders

Pharmacogenomics and Personalized Medicine, 2014
Junji Saruwatari,1 Hiroo Nakashima,1 Shoko Tsuchimine,2 Miki Nishimura,1 Naoki Ogusu,1 Norio Yasui-Furukori21Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; 2Department of ...
Saruwatari J, Nakashima H, Tsuchimine S, Nishimura M, Ogusu N, Yasui-Furukori N   +5 more
doaj  

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment [PDF]

, 2011
Background Pharmacogenetic testing holds major promise in allowing physicians to tailor therapy to patients based on genotype. However, there is little data on the impact of pharmacogenetic test results on patient and clinician choice of therapy.
Wendy Lorizio, Hope Rugo, Mary S Beattie, Simone Tchu, Teri Melese, Michelle Melisko, Alan HB Wu, H Jeffrey Lawrence, Michele Nikoloff, Elad Ziv   +9 more
core   +2 more sources

Effect of Late Second to Early Third Trimester of Pregnancy on the Activity of Renal Organic Anion Transporters (OAT1 and OAT3): A Biomarker Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnant individuals take drugs throughout pregnancy and many of these drugs (e.g., antivirals, antibiotics) are eliminated by renal organic anion transporters (OAT) 1 and OAT3. In vivo studies with OAT1/3 substrate drugs suggest that pregnancy increases renal OAT1/3 activities by 1.5‐ to 1.8‐fold.
Aarzoo Thakur, Jashvant D. Unadkat, Emily E. Fay, Nina Isoherranen, Mary F. Hebert   +4 more
wiley   +1 more source

CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia

Pharmacogenomics and Personalized Medicine, 2020
Monpat Chamnanphon,1 Sorawit Wainipitapong,2 Teeravut Wiwattarangkul,3 Phenphichcha Chuchuen,2 Kunathip Nissaipan,1,4 Weeraya Phaisal,1,4 Sookjaroen Tangwongchai,2 Chonlaphat Sukasem,5 Supeecha Wittayalertpanya,1,4 Andrea Gaedigk,6 Daruj Aniwattanapong,2
Chamnanphon M, Wainipitapong S, Wiwattarangkul T, Chuchuen P, Nissaipan K, Phaisal W, Tangwongchai S, Sukasem C, Wittayalertpanya S, Gaedigk A, Aniwattanapong D, Chariyavilaskul P   +11 more
doaj  

Altered spin state equilibrium in the T309V mutant of cytochrome P450 2D6: a spectroscopic and computational study [PDF]

, 2007
Cytochrome P450 2D6 (CYP2D6) is one of the most important cytochromes P450 in humans. Resonance Raman data from the T309V mutant of CYP2D6 show that the substitution of the conserved I-helix threonine situated in the enzyme's active site perturbs the ...
Alois Bonifacio, André R. Groenhof, Peter H. J. Keizers, Chris de Graaf, Jan N. M. Commandeur, Nico P. E. Vermeulen, Andreas W. Ehlers, Koop Lammertsma, Cees Gooijer, Gert van der Zwan, PR Ortiz Montellano de, UM Zanger, M Ingelman-Sundberg, NPE Vermeulen, P Rowland, PHJ Keizers, AD Vaz, AD Vaz, H Yeom, AL Blobaum, E Obayashi, G Truan, DC Haines, JP Clark, LS Koo, JE LeLean, N Okamoto, TG Spiro, C Jung, S Yoshioka, Z Chen, G Niaura, K Auclair, T Sjodin, A Bonifacio, T Egawa, T Deng, AL Blobaum, S Shaik, AR Groenhof, MT Green, MD Segall, GH Loew, T Omura, TJ Deng, D Kumar, GT Velde, CF Guerra, NC Handy, JP Perdew, IG Denisov, IF Sevrioukova, CA Hasemann, JK Yano, TWB Ost, TG Spiro, P Hildebrandt, J Hudecek, AJ Green, KJ McLean, MJ Groot de, M Sono, M Unno   +62 more
core   +2 more sources

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions

Clinical Pharmacology &Therapeutics, EarlyView.
Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel, Anina Zumtaugwald, Anna Bollinger, Chiara Jeiziner, Kurt E. Hersberger, Florine Wiss, Markus L. Lampert, Samuel S. Allemann, Henriette E. Meyer zu Schwabedissen, Céline K. Stäuble   +9 more
wiley   +1 more source

PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS

Архивъ внутренней медицины, 2018
The complexity of therapy of lipid metabolism disorders is not only in comorbidity and polypragmasia, but also in predicting a genetically determined response to the treatment.
A. L. Khokhlov, A. N. Yavorsky, N. O. Pozdnyakov, J. V. Rybachkova, E. S. Emelianov, A. A. Khokhlov, A. E. Miroshnikov, S. O. Pozdnyakov   +7 more
doaj   +1 more source

Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame. [PDF]

, 2016
The endoplasmic reticulum (ER)-anchored hepatic cytochromes P450 (P450s) are enzymes that metabolize endo- and xenobiotics i.e. drugs, carcinogens, toxins, natural and chemical products.
Correia, Maria Almira, Kim, Sung-Mi, Liu, Yi, Nabavi, Noushin, Wang, YongQiang   +4 more
core   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source